{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:08:23Z","timestamp":1770340103479,"version":"3.49.0"},"reference-count":65,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Dermatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1684\/ejd.2018.3447","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:16:28Z","timestamp":1696864588000},"page":"736-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe"],"prefix":"10.1684","volume":"28","author":[{"given":"Ralf","family":"Gutzmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"\u00d6hrling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"3447_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658\u201370.","journal-title":"Nat Biotechnol"},{"key":"3447_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14: 559\u201367.","journal-title":"Nat Rev Cancer"},{"key":"3447_CR3","volume-title":"IMLYGIC\u00ae (talimogene laherparepvec). Summary of product characteristics","author":"Amgen Europe B.V.","year":"2016","unstructured":"Amgen Europe B.V. IMLYGIC\u00ae (talimogene laherparepvec). Summary of product characteristics. 2016. Available at: https:\/\/doi.org\/www.medicines.org.uk\/emc\/medicine\/31351."},{"key":"3447_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10: 292\u2013303.","journal-title":"Gene Ther"},{"key":"3447_CR5","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laher-parepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33: 2780\u20138.","journal-title":"J Clin Oncol"},{"key":"3447_CR6","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1200\/JCO.2000.18.8.1614","volume":"18","author":"LE Spitler","year":"2000","unstructured":"Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000; 18: 1614\u201321.","journal-title":"J Clin Oncol"},{"key":"3447_CR7","volume-title":"Canadian Melanoma Conference (CMC)","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Collichio FA, Amatruda T, et al. Final planned overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB\/C\/IV melanoma (NCT00769704). In: Canadian Melanoma Conference (CMC), Whistler, BC, Canada, 2015."},{"key":"3447_CR8","unstructured":"Andtbacka RHI, Ross MI, Delman K, et al. Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T-VEC) in the OPTiM study and the contribution of surgery to response. Ann Surg Oncol 2014; 21: abstract 52."},{"key":"3447_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00262-017-1967-1","volume":"66","author":"R Dummer","year":"2017","unstructured":"Dummer R, Hoeller C, Gruter IP, Michielin O. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunol Immunother 2017; 66: 683\u201395.","journal-title":"Cancer Immunol Immunother"},{"key":"3447_CR10","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","volume":"26","author":"R Dummer","year":"2015","unstructured":"Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, & On behalf of the ESMO Guidelines Committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v126\u201332.","journal-title":"Ann Oncol"},{"key":"3447_CR11","first-page":"1493","volume":"34","author":"K Azijli","year":"2014","unstructured":"Azijli K, Stelloo E, Peters GJ, Van Den Eertwegh AJ. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res 2014; 34: 1493\u2013505.","journal-title":"Anticancer Res"},{"key":"3447_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","volume":"14","author":"DG Coit","year":"2016","unstructured":"Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14: 450\u201373.","journal-title":"J Natl Compr Canc Netw"},{"key":"3447_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711\u201323.","journal-title":"N Engl J Med"},{"key":"3447_CR14","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521\u201332.","journal-title":"N Engl J Med"},{"key":"3447_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-3-319-22539-5_5","volume":"167","author":"GM Boland","year":"2016","unstructured":"Boland GM, Gershenwald JE. Principles of melanoma staging. Cancer Treat Res 2016; 167: 131\u201348.","journal-title":"Cancer Treat Res"},{"key":"3447_CR16","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/cancers7030830","volume":"7","author":"E Gabriel","year":"2015","unstructured":"Gabriel E, Skitzki J. The role of regional therapies for in-transit melanoma in the era of improved systemic options. Cancers (Basel) 2015; 7: 1154\u201377.","journal-title":"Cancers (Basel)"},{"key":"3447_CR17","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1245\/s10434-013-2949-y","volume":"20","author":"KP Wevers","year":"2013","unstructured":"Wevers KP, Kruijff S, Speijers MJ, Bastiaannet E, Muller Kobold AC, Hoekstra HJ. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma. Ann Surg Oncol 2013; 20: 2772\u20139.","journal-title":"Ann Surg Oncol"},{"key":"3447_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3109\/0284186X.2015.1043026","volume":"54","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol 2015; 54: 961\u201370.","journal-title":"Acta Oncol"},{"key":"3447_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/bjd.14347","volume":"174","author":"AL Frauchiger","year":"2016","unstructured":"Frauchiger AL, Mangana J, Rechsteiner M, et al. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. Br J Dermatol 2016; 174: 823\u201330.","journal-title":"Br J Dermatol"},{"key":"3447_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12032-016-0879-9","volume":"34","author":"J Cicenas","year":"2017","unstructured":"Cicenas J, Tamosaitis L, Kvederaviciute K, et al. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Med Oncol 2017; 34: 26.","journal-title":"Med Oncol"},{"key":"3447_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.7326\/0003-4819-153-9-201011020-00008","volume":"153","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT. Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Intern Med 2010; 153: 587\u201391.","journal-title":"Ann Intern Med"},{"key":"3447_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ejso.2016.10.014","volume":"43","author":"VC Amann","year":"2017","unstructured":"Amann VC, Ramelyte E, Thurneysen S, et al. Developments in targeted therapy in melanoma. Eur J Surg Oncol 2017; 43: 581\u201393.","journal-title":"Eur J Surg Oncol"},{"key":"3447_CR23","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1016\/S1470-2045(15)00003-0","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob JJ, Long GV, Schadendorf D, Flaherty K. Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. Lancet Oncol 2015; 16: e522\u20136.","journal-title":"Lancet Oncol"},{"key":"3447_CR24","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.2147\/OTT.S115245","volume":"9","author":"KJ Harrington","year":"2016","unstructured":"Harrington KJ, Andtbacka RHI, Collichio F, et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with stage IIIB\/C and IVM1a melanoma: subanalysis of the phase III OPTiM trial. Onco Targets Ther 2016; 9: 7081\u201393.","journal-title":"Onco Targets Ther"},{"key":"3447_CR25","doi-asserted-by":"crossref","unstructured":"Andtbacka R, Kaufman H, Collichio F, et al. Durable complete responses (CRs) in patients (pts) with stage IIIB-IV melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM. Ann Surg Oncol 2016; 20: abstract 68.","DOI":"10.1016\/S0959-8049(16)31852-4"},{"key":"3447_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-017-0276-8","volume":"5","author":"HL Kaufman","year":"2017","unstructured":"Kaufman HL, Andtbacka RHI, Collichio FA, et al. Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. J Immunother Cancer 2017; 5:72.","journal-title":"J Immunother Cancer"},{"key":"3447_CR27","doi-asserted-by":"publisher","first-page":"948302","DOI":"10.5402\/2012\/948302","volume":"2012","author":"R Shashanka","year":"2012","unstructured":"Shashanka R, Smitha BR. Head and neck melanoma. ISRN Surg 2012; 2012: 948302.","journal-title":"ISRN Surg"},{"key":"3447_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/107327480501200406","volume":"12","author":"MA Kienstra","year":"2005","unstructured":"Kienstra MA, Padhya TA. Head and neck melanoma. Cancer Control 2005; 12: 242\u20137.","journal-title":"Cancer Control"},{"key":"3447_CR29","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/hed.24522","volume":"38","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka RH, Agarwala SS, Ollila DW, et al. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colonystimulating factor for the treatment of unresected stage IIIB\/IIIC\/IV melanoma. Head Neck 2016; 38: 1752\u20138.","journal-title":"Head Neck"},{"key":"3447_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jdcr.2017.02.011","volume":"3","author":"JT Blackmon","year":"2017","unstructured":"Blackmon JT, Stratton MS, Kwak Y, et al. Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec. JAAD Case Rep 2017; 3: 280\u20133.","journal-title":"JAAD Case Rep"},{"key":"3447_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017; 170: 1109\u201319.","journal-title":"Cell"},{"key":"3447_CR32","first-page":"39","volume":"31","author":"J Malvehy","year":"2017","unstructured":"Malvehy J, Samoylenko I, Schadendorf D, et al. Relationship between talimogene laherparepvec and intratumoral CD8+ density in patients with unresectable stage IIIB-IVM1c melanoma: interim efficacy, safety and biomarker results of a phase 2 study. J Eur Acad Dermatol Venereol 2017; 31: 39.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3447_CR33","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375: 1845\u201355.","journal-title":"N Engl J Med"},{"key":"3447_CR34","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017; 377: 1813\u201323.","journal-title":"N Engl J Med"},{"key":"3447_CR35","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del VM, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824\u201335.","journal-title":"N Engl J Med"},{"key":"3447_CR36","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.ejca.2013.12.015","volume":"50","author":"C Gaudy-Marqueste","year":"2014","unstructured":"Gaudy-Marqueste C, Archier E, Grob A, et al. Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. Eur J Cancer 2014; 50: 1120\u20134.","journal-title":"Eur J Cancer"},{"key":"3447_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","volume":"4","author":"H Rehman","year":"2016","unstructured":"Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer 2016; 4: 53.","journal-title":"J Immunother Cancer"},{"key":"3447_CR38","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.2147\/OTT.S133699","volume":"10","author":"KJ Harrington","year":"2017","unstructured":"Harrington KJ, Michielin O, Malvehy J, et al. A practical guide to the handling and administration of talimogene laherparepvec in Europe. Onco Targets Ther 2017; 10: 3867\u201380.","journal-title":"Onco Targets Ther"},{"key":"3447_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1188\/16.ONF.219-226","volume":"43","author":"B Hoffner","year":"2016","unstructured":"Hoffner B, Iodice GM, Gasal E. Administration and handling of talimogene laherparepvec: an intralesional oncolytic immunotherapy for melanoma. Oncol Nurs Forum 2016; 43: 219\u201326.","journal-title":"Oncol Nurs Forum"},{"key":"3447_CR40","first-page":"76","volume":"21","author":"V Seery","year":"2017","unstructured":"Seery V. Intralesional therapy: consensus statements for bestpractices in administration from the melanoma nursing initiative. Clin J Oncol Nurs 2017; 21: 76\u201386.","journal-title":"Clin J Oncol Nurs"},{"key":"3447_CR41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/0018578717749926","volume":"53","author":"A McBride","year":"2018","unstructured":"McBride A, Valgus J, Parsad S, Sommermann EM, Nunan R. Pharmacy operationalization of the intralesional oncolytic immunotherapy talimogene laherparepvec. Hosp Pharm 2018; 53: 296\u2013302.","journal-title":"Hosp Pharm"},{"key":"3447_CR42","unstructured":"Amgen Inc. IMLYGIC\n                           \u2122\n                           safety data sheet. 2016. Available at: http:\/\/msds.amgen.com\/\u223c\/media\/amgen\/repositorysites\/msds-amgen-com\/imlygicsds.ashx\/\u223c\/media\/amgen\/repositorysites\/msds-amgen-com\/imlygicsds.ashx."},{"key":"3447_CR43","unstructured":"Andtbacka R, Kaufman H, Harrington K, et al. Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM. In: 16th World Congress on Cancer of the Skin\u00ae and 12th Congress of the European Association of Dermato-Oncology, Vienna, Austria, August 31-September 3, 2016; P049."},{"key":"3447_CR44","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.2147\/OTT.S115245","volume":"9","author":"KJ Harrington","year":"2016","unstructured":"Harrington KJ, Andtbacka RHI, Collichio F, et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB\/C and IVM1a melanoma: subanalysis of the phase III OPTiM trial. Onco Targets Ther 2016; 9: 7081\u201393.","journal-title":"Onco Targets Ther"},{"key":"3447_CR45","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","volume":"12","author":"JC Hu","year":"2006","unstructured":"Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGMCSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737\u201347.","journal-title":"Clin Cancer Res"},{"key":"3447_CR46","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-10-0196","volume":"16","author":"KJ Harrington","year":"2010","unstructured":"Harrington KJ, Hingorani M, Tanay MA, et al. Phase I\/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III\/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16: 4005\u201315.","journal-title":"Clin Cancer Res"},{"key":"3447_CR47","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763\u201371.","journal-title":"J Clin Oncol"},{"key":"3447_CR48","unstructured":"Andtbacka RHI, Mehnert J, Nemunaitis JJ, et al. Phase 2 trial evaluating biodistribution and shedding of talimogene laherparepvec (T-VEC) in patients (pts) with unresectable stages IIIB\/IV melanoma. In: Proceedings from the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2017; abstract 16. Available at: http:\/\/www.abstractsonline.com\/pp8\/#!\/4399\/presentation\/1003."},{"key":"3447_CR49","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","volume":"17","author":"HL Kaufman","year":"2010","unstructured":"Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17: 718\u201330.","journal-title":"Ann Surg Oncol"},{"key":"3447_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1\u201310.","journal-title":"Immunity"},{"key":"3447_CR51","doi-asserted-by":"publisher","first-page":"6190","DOI":"10.1158\/1078-0432.CCR-17-0681","volume":"23","author":"AK Moesta","year":"2017","unstructured":"Moesta AK, Cooke K, Piasecki J, et al. Local delivery of OncoVEXmGM-CSF generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade. Clin Cancer Res 2017; 23: 6190\u2013202.","journal-title":"Clin Cancer Res"},{"key":"3447_CR52","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka RH, Ross M, Puzanov I, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol 2016; 23: 4169\u201377.","journal-title":"Ann Surg Oncol"},{"key":"3447_CR53","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412\u201320.","journal-title":"Clin Cancer Res"},{"key":"3447_CR54","doi-asserted-by":"crossref","unstructured":"Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol 2014; 32(5S): abstract 9002.","DOI":"10.1200\/jco.2014.32.15_suppl.9002"},{"key":"3447_CR55","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Hamid O, Ribas A, et al. Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. J Clin Oncol 2015; 33: abstract 3000.","DOI":"10.1200\/jco.2015.33.15_suppl.3000"},{"key":"3447_CR56","unstructured":"Harrington K, Kaufman H, Middleton M, Ottensmeier C, Downey G, Andtbacka RHI. Patterns of clinical response in talimogene laher-parepvec treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial. In: Oral presentation at the 16th World Congress on Cancers of the Skin\u00ae and 12th Congress of the European Association of Dermato-Oncology, Vienna, Austria, August 31-September 3, 2016; SY12\u20135."},{"key":"3447_CR57","unstructured":"Kaufman H. Secondary endpoints from OPTiM: a multicenter, randomized phase 3 trial of talimogene laherparepvec vs GM-CSF for the treatment of unresected stage IIIB\/C and IV melanoma. Eur J Cancer 2013;49: abstract 3733 (P479)."},{"key":"3447_CR58","doi-asserted-by":"publisher","first-page":"22847","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 22847.","journal-title":"Eur J Cancer"},{"key":"3447_CR59","first-page":"13845","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Litiere S, et al. RECIST 1.1 \u2014 Standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer 2016; 62: 13845.","journal-title":"Eur J Cancer"},{"key":"3447_CR60","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4143\/crt.2005.37.5.290","volume":"37","author":"JH Choi","year":"2005","unstructured":"Choi JH, Ahn MJ, Rhim HC, et al. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Res Treat 2005; 37: 290\u20133.","journal-title":"Cancer Res Treat"},{"key":"3447_CR61","doi-asserted-by":"publisher","first-page":"iv369","DOI":"10.1093\/annonc\/mdu342.23","volume":"25","author":"O Bohnsack","year":"2014","unstructured":"Bohnsack O, Hoos A, Ludajic K. Adaptation of the immune related response criteria: irRECIST. Ann Oncol 2014; 25: iv369 (abstract 4958 and poster 1070P).","journal-title":"Ann Oncol"},{"key":"3447_CR62","volume-title":"QuintilesIMSTM White Paper","author":"C Klifa","year":"2016","unstructured":"Klifa C, Zaim S, Guglielmetti F, Anthony FH. Imaging criteria for treatment response in immuno-oncology clinical trials. In: QuintilesIMSTM White Paper. 2016. Available at: http:\/\/www.quintiles.com\/library\/white-papers\/imaging-criteria-for-treatment-response-in-immunooncology-clinical-trials."},{"key":"3447_CR63","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nrd.2016.254","volume":"15","author":"E Dolgin","year":"2016","unstructured":"Dolgin E. Cancer immunology community seeks better end points. Nat Rev Drug Discov 2016; 15: 807\u20139.","journal-title":"Nat Rev Drug Discov"},{"key":"3447_CR64","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143\u201352.","journal-title":"Lancet Oncol"},{"key":"3447_CR65","unstructured":"Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laher-parepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol 2017: JCO2017737379."}],"container-title":["European Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2018.3447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ejd.2018.3447\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2018.3447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2018.3447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:21:11Z","timestamp":1741191671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2018.3447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3447"],"URL":"https:\/\/doi.org\/10.1684\/ejd.2018.3447","relation":{},"ISSN":["1952-4013"],"issn-type":[{"value":"1952-4013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"25 April 2018","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 Mai 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}